88 related articles for article (PubMed ID: 35843997)
1. Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers.
Drilon A; Tan DSW; Lassen UN; Leyvraz S; Liu Y; Patel JD; Rosen L; Solomon B; Norenberg R; Dima L; Brega N; Shen L; Moreno V; Kummar S; Lin JJ
JCO Precis Oncol; 2022 Jan; 6():e2100418. PubMed ID: 35085007
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study).
Orbach D; Carton M; Khadir SK; Feuilly M; Kurtinecz M; Phil D; Vokuhl C; Koscielniak E; Pierron G; Lemelle L; Sparber-Sauer M
ESMO Open; 2024 May; 9(5):103006. PubMed ID: 38657345
[TBL] [Abstract][Full Text] [Related]
3. Tackling Challenges in Assessing the Economic Value of Tumor-Agnostic Therapies: A Cost-Effectiveness Analysis of Pembrolizumab as a Case Study.
Chen Y; Martin P; Inoue LYT; Basu A; Carlson JJ
Value Health; 2024 Mar; ():. PubMed ID: 38548177
[TBL] [Abstract][Full Text] [Related]
4. Larotrectinib versus historical standard of care in patients with infantile fibrosarcoma: protocol of EPI-VITRAKVI.
Carton M; Del Castillo JP; Colin JB; Kurtinecz M; Feuilly M; Pierron G; Arvis P; Khadir SK; Sparber-Sauer M; Orbach D
Future Oncol; 2023 Aug; 19(24):1645-1653. PubMed ID: 37133249
[TBL] [Abstract][Full Text] [Related]
5. Healthcare decision-making for tumour-agnostic therapies in Europe: lessons learned.
Hogervorst MA; van Hattem CC; Sonke GS; Mantel-Teeuwisse AK; Goettsch WG; Bloem LT
Drug Discov Today; 2024 May; 29(7):104031. PubMed ID: 38796096
[TBL] [Abstract][Full Text] [Related]
6. Larotrectinib versus infigratinib for adult patients with both glioma and tyrosine kinase alterations after failure of initial therapies: Efficacy and safety analysis.
Chen Y; Ma J; Gao Q; Gai Y; Sun Y; Wang M
Clinics (Sao Paulo); 2024; 79():100329. PubMed ID: 38330791
[TBL] [Abstract][Full Text] [Related]
7. Disseminated juvenile xanthogranulomas with underlying neurotrophic tyrosine receptor kinase fusion and response to larotrectinib.
Kim EJ; Reusch DB; Anthony H; Schmidt B; Corey K; Degar B; Huang JT
Br J Dermatol; 2024 Jan; 190(2):283-284. PubMed ID: 37930319
[No Abstract] [Full Text] [Related]
8. Current therapeutic landscape and resistance mechanisms to larotrectinib.
Xie W; Xu J; Lu S; Zhang Y
Cancer Biol Med; 2024 Feb; 20(12):967-71. PubMed ID: 38318928
[No Abstract] [Full Text] [Related]
9. Important Considerations for Real-World Analysis of Neurotrophic Tyrosine Receptor Kinase Fusion Cancer and Tropomyosin Receptor Kinase Inhibitors.
Brose MS; Hong DS; Drilon A
JCO Precis Oncol; 2023 Sep; 7():e2300217. PubMed ID: 37769225
[No Abstract] [Full Text] [Related]
10. Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors.
Rosen EY; Schram AM; Young RJ; Schreyer MW; Hechtman JF; Shu CA; Ku NC; Hyman DM; Drilon A
JCO Precis Oncol; 2019; 3():. PubMed ID: 32914009
[No Abstract] [Full Text] [Related]
11. HEcoPerMed, personalized medicine from a health economic perspective: lessons learned and potential opportunities ahead.
Rutten-van Mölken M; Versteegh M; Nagy B; Wordsworth S
Per Med; 2023 Jul; 20(4):299-303. PubMed ID: 37736874
[No Abstract] [Full Text] [Related]
12. Marked effect of larotrectinib on primary cutaneous secretory carcinoma: A case report.
Hayakawa K; Irisawa R; Umefune R; Mae K; Shimada Y; Takahashi R; Nagao T; Harada K
J Dermatol; 2024 Apr; ():. PubMed ID: 38605458
[No Abstract] [Full Text] [Related]
13. Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic
Suh K; Carlson JJ; Xia F; Williamson T; Sullivan SD
J Comp Eff Res; 2022 Oct; 11(14):1011-1019. PubMed ID: 35993247
[No Abstract] [Full Text] [Related]
14. Economic Evaluation of a Tumour-Agnostic Therapy: Dutch Economic Value of Larotrectinib in TRK Fusion-Positive Cancers.
Michels RE; Arteaga CH; Peters ML; Kapiteijn E; Van Herpen CML; Krol M
Appl Health Econ Health Policy; 2022 Sep; 20(5):717-729. PubMed ID: 35843997
[TBL] [Abstract][Full Text] [Related]
15. The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma.
Suh K; Carlson JJ; Xia F; Williamson T; Sullivan SD
J Manag Care Spec Pharm; 2022 Jun; 28(6):622-630. PubMed ID: 35362337
[No Abstract] [Full Text] [Related]
16. Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data.
Bokemeyer C; Paracha N; Lassen U; Italiano A; Sullivan SD; Marian M; Brega N; Garcia-Foncillas J
JCO Precis Oncol; 2023 Jan; 7():e2200436. PubMed ID: 36689698
[TBL] [Abstract][Full Text] [Related]
17. The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.
Roth JA; Carlson JJ; Xia F; Williamson T; Sullivan SD
J Manag Care Spec Pharm; 2020 Aug; 26(8):981-986. PubMed ID: 32329651
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
